Gonzalez-Motta Alejandro, Cuevas Diana M, Jacobo Javier A, Cardona-Zorrilla Andres F, Bobadilla Ivan A
Radiotherapy Functional Unit, Centro de Tratamiento e Investigación sobre Cáncer (CTIC), Bogota, COL.
Research Group GIGA, Universidad del Bosque and Centro de Tratamiento e Investigación sobre Cáncer (CTIC), Bogota, COL.
Cureus. 2025 May 8;17(5):e83747. doi: 10.7759/cureus.83747. eCollection 2025 May.
Sacral chordoma is a rare and locally aggressive neoplasm that presents significant treatment challenges due to its anatomical location and tendency toward local invasion. Although complete surgical resection remains the gold standard for a potential cure, the high surgical morbidity necessitates alternative, less invasive treatment approaches. Robotic radiosurgery using the CyberKnife system has emerged as a promising option, particularly for patients who refuse surgery or are unsuitable surgical candidates. Furthermore, the precise delivery of high-dose radiation is crucial, as even minor sacral movements can affect dose distribution and treatment outcomes. We present the case of a 27-year-old male with a confirmed diagnosis of sacral chordoma who experienced progressive tumor growth. Given the high morbidity associated with surgical resection in the sacral region and the patient's preference for avoiding surgery, a multidisciplinary team opted for stereotactic radiosurgery (SRS) using CyberKnife. Robotic radiosurgery with real-time image guidance accounted for minor sacral movements during treatment delivery. The patient received 600-700 centigray (cGy) with a simultaneous integrated boost of radiation every other day, culminating in a total dose of 3,000 and 3,500 cGy to the planning target volume 30 and planning target volume 35, respectively, defined as the sacral mass with and without subclinical extension plus an appropriate margin. The quantitative analysis of intra-fractional patient movements recorded during treatment delivery revealed a range of displacements: 0.0-1.0 mm along the x-axis, 0.0- 1.5 millimeters (mm) along the y-axis, and 0.0- 1.0 mm along the z-axis. Rotational deviations were also assessed, with roll ranging from 0.0° to 0.8°, pitch from 0.0° to 0.4°, and jaw rotation from 0.0° to 0.7°. Following the completion of treatment on July 24, 2023, the patient reported a 90% reduction in pain. Subsequent clinical and radiological evaluations demonstrated substantial lesion regression with minimal toxicity, preserving the patient's quality of life. This case reinforces the expanding body of evidence supporting advanced SRS for managing complex tumors. The successful application of CyberKnife in this sacral chordoma case, along with robust motion management strategies, highlights its potential as a safe and effective alternative when conventional surgery is not feasible.
骶骨脊索瘤是一种罕见的、具有局部侵袭性的肿瘤,因其解剖位置和局部侵袭倾向,在治疗上面临重大挑战。尽管完整的手术切除仍然是实现潜在治愈的金标准,但手术并发症发生率高,因此需要采用侵入性较小的替代治疗方法。使用射波刀系统的机器人放射外科已成为一种有前景的选择,特别是对于拒绝手术或不适合手术的患者。此外,精确输送高剂量辐射至关重要,因为即使骶骨的轻微移动也会影响剂量分布和治疗效果。我们报告了一例确诊为骶骨脊索瘤的27岁男性患者,其肿瘤呈进行性生长。鉴于骶骨区域手术切除相关的高并发症发生率以及患者对避免手术的偏好,多学科团队选择使用射波刀进行立体定向放射外科(SRS)治疗。具有实时图像引导的机器人放射外科能够在治疗过程中应对骶骨的轻微移动。患者每隔一天接受600 - 700厘戈瑞(cGy)的辐射,并同时进行增量照射,最终分别向计划靶区30和计划靶区35给予3000和3500 cGy的总剂量,计划靶区30和计划靶区35分别定义为伴有和不伴有亚临床扩展及适当边缘的骶骨肿块。对治疗过程中记录的分次治疗期间患者运动的定量分析显示,位移范围为:x轴0.0 - 1.0毫米,y轴0.0 - 1.5毫米,z轴0.0 - 1.0毫米。还评估了旋转偏差,滚动范围为0.0°至0.8°,俯仰范围为0.0°至0.4°,颌部旋转范围为0.0°至0.7°。在2023年7月24日完成治疗后,患者报告疼痛减轻了90%。随后的临床和影像学评估显示病变明显消退,毒性极小,保留了患者的生活质量。该病例进一步证明了支持先进SRS治疗复杂肿瘤的证据不断增加。射波刀在该骶骨脊索瘤病例中的成功应用以及强大的运动管理策略,凸显了其在传统手术不可行时作为安全有效替代方法的潜力。